We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
20 Oct 2021 - 22 Oct 2021
21 Oct 2021 - 24 Oct 2021
Virtual Venue

Elevated Circulating Fatty Acid Synthase Is a Diagnostic Biomarker for Peripheral Artery Disease

By LabMedica International staff writers
Posted on 11 Oct 2021
Print article
Image: Pictured is a cross section of a peripheral artery from the leg of a patient with chronic limb-threatening ischemia (CLTI), a condition in which heavy plaque formation causes a severe narrowing of the arteries (Photo courtesy of Zayed Research Laboratory, Washington University School of Medicine)
Image: Pictured is a cross section of a peripheral artery from the leg of a patient with chronic limb-threatening ischemia (CLTI), a condition in which heavy plaque formation causes a severe narrowing of the arteries (Photo courtesy of Zayed Research Laboratory, Washington University School of Medicine)
Elevated levels of a soluble form of the enzyme fatty acid synthase (sFSA) in the blood have been linked to development of the severe vascular disorder peripheral artery disease (PAD).

Fatty acid synthase is a multi-enzyme protein that catalyzes fatty acid synthesis. It is not a single enzyme but a whole enzymatic system composed of two identical multifunctional polypeptides, in which substrates are handed from one functional domain to the next. The main function of FSA is to catalyze the synthesis of palmitate (C16:0, a long-chain saturated fatty acid) from acetyl-CoA and malonyl-CoA, in the presence of NADPH.

In 2015, about 155 million people had PAD worldwide, and it becomes more common with age. In the developed world, PAD affects about 5.3% of 45- to 50-year-olds and 18.6% of 85- to 90-year-olds. In the United States PAD impacts some 12 million people. Among them at least 10% will progress to develop chronic limb-threatening ischemia (CLTI), a condition characterized by severe lower extremity arterial insufficiency, rest pain, non-healing wounds/ulcers, and gangrene.

There are currently no serum-based evaluations that can corroborate the severity of PAD. Therefore, in order to improve prognosis, the Global Vascular Guidelines recently highlighted the need for early diagnosis and aggressive medical management of patients. In this regard, investigators at Washington University School of Medicine (St. Louis, MO, USA) assessed the prevalence of elevated serum fatty acid synthase (cFAS) in patients with CLTI and evaluated the accuracy of its use in detecting this condition. This approach was based on prior studies showing that serum circulating FAS was elevated in patients with atherosclerotic carotid artery stenosis, and FAS content in carotid plaque was higher in maximally diseased segments.

For the current study, the investigators obtained and analyzed blood samples from 87 patients before they underwent vascular surgery to treat CLTI. Results revealed that elevated cFAS content, type II diabetes, and smoking were independently associated with CLTI and could detect the presence of CLTI with 83% accuracy. Levels cFAS in the blood were associated with the FAS content of plaque sampled from the femoral artery, the main vessel supplying blood to the legs. In addition, cFAS was found to circulate through the bloodstream while bound to the cholesterol transporter, low-density lipoprotein (LDL).

“These patients are at risk of losing their legs, which is devastating to quality of life,” said senior author Dr. Mohamed A. Zayed, associate professor of surgery and radiology at Washington University School of Medicine. “They lose their capacity to walk, and about half of them die within the next two years. We need to identify these patients sooner, so we can help treat them aggressively much earlier in the disease course. Our data suggest that levels of cFAS in the blood could be an accurate predictor for which patients are at high risk of the severe forms of this condition.”

“Oftentimes, I will see patients in my practice who have high LDL but are otherwise healthy individuals - they do not have evidence of disease in their arteries,” said Dr. Zayed. “Our guidelines tell us to be aggressive in treating these patients. But my suspicion is the problem is not just LDL. Rather, the problem is enzymes that are attached to LDL that are conferring the cardiovascular disease that we see, particularly in the peripheral arteries, as well as the coronary arteries that deliver blood to the heart and the carotid arteries that deliver blood to the brain.”

The study was published in the September 29, 2021, online edition of the journal Scientific Reports.

Related Links:
Washington University School of Medicine

New
Gold Supplier
SARS-CoV-2/Flu A/B & RSV Test
RespiBio Panel 3 (RBRP3)
New
Gold Supplier
Fully Automated ELISA Workstation
EUROLabWorkstation ELISA
New
Silver Supplier
Automated RPR Syphilis Test
Automated RPR Test Kit
New
Automated Urinalysis Solution
DxU Iris Workcell

Print article

Channels

Clinical Chem.

view channel
Image: Simoa is an ultra-sensitive immunoassay technology that allow detection of proteins and nucleic acids at lowest possible levels (Photo courtesy of Quanterix)

Plasma Amyloid-β 42/40 Assays Compared in Alzheimer Disease

Blood-based tests for brain amyloid-β (Aβ) pathology are needed for widespread implementation of Alzheimer disease (AD) biomarkers in clinical care and to facilitate patient screening and monitoring of... Read more

Hematology

view channel
Image: Bone marrow aspirate from a patient with peripheral T-cell lymphoma (Photo courtesy of Peter Maslak, MD)

Mutation Analysis Links Angioimmunoblastic T-Cell Lymphoma to Clonal Hematopoiesis

Peripheral T-cell lymphoma (PTCL) is a heterogeneous group of lymphoid tumors and encompass peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS), angioimmunoblastic T-cell lymphoma (AITL), and... Read more

Immunology

view channel
Image: The BD LSRFortessa X-20 Cell Analyzer can be configured with up to five lasers to detect up to 20 parameters simultaneously to support ever increasing demands in multicolor flow cytometry (Photo courtesy of BD Biosciences)

Highly Multiplexed Cell Surface Protein Analyzed Via Flow Cytometry

Modern immunologic studies increasingly requires high-dimensional analyses to understand the complex milieu of cell types that comprise the tissue microenvironments of disease. One of the cornerstones... Read more

Pathology

view channel
Image: Characteristic bronchoalveolar lavage findings of diffuse alveolar hemorrhage (Photo courtesy of Peter C. Bauer, MD)

Bronchoalveolar Lavage Cell Pattern Determined for Diffuse Alveolar Hemorrhage

Diffuse alveolar hemorrhage (DAH) is a clinicopathological syndrome that describes the accumulation of intra-alveolar red blood cells originating from the alveolar capillaries. DAH can induce severe respiratory... Read more

Industry

view channel
Image: GastroPanel Quick Test (Photo courtesy of Biohit Healthcare)

Biohit’s Innovative GastroPanel Quick Test Receives CE Mark

Biohit Healthcare’s (Helsinki, Finland) GastroPanel Quick Test, the latest innovation in its unique GastroPanel product family, is now CE marked. The GastroPanel Quick Test is intended for diagnosing... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.